Target intelligence / Profile preview

Integrin alpha FG-GAP repeat containing 2 (ITFG2)

Target
ITFG2
Molecular classification
Protein coding gene, FG-GAP repeat-containing protein, Regulatory protein (KICSTOR complex subunit), Other
01

Overview

Integrin alpha FG-GAP repeat containing 2 (ITFG2) is a highly conserved intracellular protein with two FG-GAP domains, which mediate critical protein-protein interactions involved in diverse cellular processes[1][4]. ITFG2 serves as a subunit of the KICSTOR complex, and is a regulator of the amino acid-sensing branch of the mTORC1 signaling pathway; it recruits the GATOR1 complex to lysosomal membranes and allows its interaction with other mTOR regulatory factors, thereby negatively regulating mTORC1 activity in the absence of amino acids or glucose[3][5][8]. ITFG2 also plays key roles in the differentiation and maturation of B cells, immune response modulation, and maintenance of immunoglobulin levels, with additional implications in the development of autoimmune diseases

Other names
ITFG2FGGAP1 (previous HGNC symbol)Integrin-α FG-GAP repeat-containing protein 22700050P07Rik (mouse)
02

Mechanism of action

No specific drug mechanism of action targeting ITFG2 is reported; its regulatory role in mTOR pathway suggests that inhibitors or activators of mTOR pathway might indirectly affect ITFG2 function

03

Biological functions

Negative regulation of mTORC1 signaling pathway in response to amino acid and glucose starvationB cell differentiation and maturationCellular response to stimuli (amino acid starvation, glucose starvation)Negative regulation of immune response
04

Disease associations

Autoimmune diseases (notably lupus, through regulation of B cell responses)Developmental and epileptic encephalopathyDeafness, autosomal recessive 27Other (roles in cell migration and plasma cell distribution may have implications in other immune/hematologic diseases)
05

Safety considerations

No safety concerns directly linked to ITFG2 targeting in current therapeutic strategies; however, global effect on mTOR pathway may pose general safety challenges typical for this pathway, such as effects on cell proliferation, metabolism, and immune homeostasis

Beyond the preview

Go deeper on Integrin alpha FG-GAP repeat containing 2 (ITFG2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin alpha FG-GAP repeat containing 2 (ITFG2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call